Research use only. Semax is sold strictly as a reference material for in-vitro and laboratory research. Nothing here is medical advice, a nootropic recommendation, a dosing protocol, or a statement of human efficacy — it summarises how the published literature characterises the peptide. Every batch we list is published with its independent Janoshik HPLC certificate.
What Semax is
Semax is a synthetic heptapeptide developed in Russia, structurally based on the ACTH(4–10) fragment of adrenocorticotropic hormone, with a proline-glycine-proline tail added for stability. Its defining characteristic in the literature is the most important thing to understand about it: it retains the neurotropic activity associated with the ACTH fragment while lacking the corticotropic (steroidogenic) activity — that is, it is studied for brain effects without driving the adrenal/cortisol response of full ACTH.
What the research investigates
- BDNF and neurotrophic signalling. A recurring finding across studies is upregulation of brain-derived neurotrophic factor (BDNF) and related neurotrophins.
- Neuroprotection / ischemia models. Much of the Russian clinical and preclinical literature examines Semax in stroke and cerebral-ischemia contexts.
- Cognition and attention. Studies investigate effects on learning, memory consolidation, and attention in animal models — the basis of its “nootropic” research reputation.
- Blood-brain-barrier penetration. Semax is studied as a BBB-penetrant peptide, often administered intranasally in research.
Semax and Selank — the research pairing
Semax is frequently studied alongside Selank, another Russian regulatory peptide. The two are treated as complementary in the literature: Semax on the cognitive/neurotrophic side, Selank on the anxiolytic/calming side. Both also appear in Bastion’s cognitive stack grouping.
What the literature does NOT establish
No validated human dosing protocol, no established cognitive-enhancement claim for healthy humans outside the Russian clinical literature, and no long-term safety data are asserted here. A large share of the research comes from a single national research tradition, which is worth noting when weighing the evidence. Treat Semax strictly as a laboratory research compound.
Handling and reconstitution
Semax ships as lyophilised powder and must be reconstituted before laboratory work; reconstitution volume sets concentration per unit, so calculate it with our reconstitution guide rather than estimating.
Verifying what you receive
The Semax we list is published with the independent Janoshik HPLC certificate that accompanies its batch — see the lab results archive; the task ID resolves on Janoshik’s own domain.
Frequently asked questions
What is Semax derived from?
It is a synthetic heptapeptide based on the ACTH(4–10) fragment with a stabilising Pro-Gly-Pro tail. It keeps the neurotropic activity of that fragment without the corticotropic (cortisol-driving) activity.
What is Semax researched for?
Primarily BDNF/neurotrophic signalling, neuroprotection in ischemia models, and cognition/attention in animal models — the basis of its nootropic research reputation.
How is Semax different from Selank?
They are complementary regulatory peptides: Semax is studied on the cognitive/neurotrophic side, Selank on the anxiolytic side. They are frequently co-studied.
How is it administered in research?
Semax is studied as a blood-brain-barrier-penetrant peptide and is often given intranasally in research settings.
How do I verify the purity of the batch I receive?
Each batch we list is published with its independent Janoshik HPLC certificate and a public verify link on Janoshik’s own domain.
Is Semax for human use?
No. It is sold strictly as a research-use-only reference material and is not intended for human or veterinary use.
Summary
Semax is an ACTH(4–10)-derived heptapeptide studied for neurotrophic and neuroprotective effects without corticotropic activity — the cognitive half of the Semax/Selank research pairing. Match it to the research question, reconstitute it correctly, and confirm the batch against its published Janoshik certificate.